Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
- DOI
- 10.1038/s41698-025-01253-5
- Published
- 2026 Jan 13
- Container
- NPJ precision oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41698-025-01253-5,
title = {Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.},
author = {Pu T and Peddle AM and Wirapati P and Tsantoulis P and Wu Q and Hong Y and Samuel L and Desai J and Riener M and Saridaki Z and Cunningham D and Tejpar S},
year = {2026},
journal = {NPJ precision oncology},
doi = {10.1038/s41698-025-01253-5},
url = {https://doi.org/10.1038/s41698-025-01253-5}
}RIS
TY - JOUR TI - Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial. AU - Pu T AU - Peddle AM AU - Wirapati P AU - Tsantoulis P AU - Wu Q AU - Hong Y AU - Samuel L AU - Desai J AU - Riener M AU - Saridaki Z AU - Cunningham D AU - Tejpar S PY - 2026 JO - NPJ precision oncology DO - 10.1038/s41698-025-01253-5 UR - https://doi.org/10.1038/s41698-025-01253-5 ER -
APA
T, P., AM, P., P, W., P, T., Q, W., Y, H., L, S., J, D., M, R., Z, S., D, C., & S, T. (2026). Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.. NPJ precision oncology. https://doi.org/10.1038/s41698-025-01253-5
Source records
- pubmed · retrieved 2026-09-26T20:22:35.718Z